[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] QIU M Z,SHI S M,CHEN Z H,et al.Frequency and clinicopathological features of metastasis to liver,lung,bone,and brain from gastric cancer:a SEER-based study[J].Cancer Med,2018,7(8):3662-3672.
[3] KESHAV S H,MOY R H,REINER S L,et al.Gastric cancer and the immune system:the key to improving outcomes?[J].Cancers(Basel),2022,14(23):5940.
[4] LI X,CHEN Z,ZHANY Y,et al.Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis-a population based analysis[J].Front Oncol,2023,13:1064790.
[5] GUO S,LI J,HUANG Z,et al.The CBS-H2S axis promotes liver metastasis of colon cancer by upregulating VEGF through AP-1 activation[J].Br J Cancer,2022,126(7):1055-1066.
[6] CEVIK M,NAMAL E,DINC-SENER N,et al.Investigation of vascular endothelial growth factor polymorphisms on risk,metastasis,laterality,and prognosis of colorectal cancer in Turkish subjects[J].Genet Test Mol Biomarkers,2022,26(5):298-306.
[7] 张祥,季雪梅.Septin9基因甲基化在胃癌诊断中的研究进展[J].现代医学,2023,51(7):1029-1032.
[8] PENG J,ZHU Q,PENG Z,et al.Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab(PD-1/CTLA-4 bispecific):a case report[J].Front Immunol,2022,13:1049518.
[9] MAKIYAMA A,SUKAWA Y,KASHIWADA T,et al.Randomized,phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer:WJOG7112G(T-ACT Study)[J].J Clin Oncol,2020,38(17):1919-1927.
[10] HU C T,ZHOU Y C,ZU L D,et al.High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab:a case report[J].Ann Palliat Med,2021,10(5):5846-5852.
[11] AL KAWAS H,SAAID I,JANK P,et al.How VEGF-A and its splice variants affect breast cancer development-clinical implications[J].Cell Oncol(Dordr),2022,45(2):227-239.
[12] YANG Y,CAO Y.The impact of VEGF on cancer metastasis and systemic disease[J].Semin Cancer Biol,2022,86(Pt 3):251-261.
[13] EGUCHI R,KAWABE J I,WAKABAYASHI I.VEGF-independent angiogenic pactors:beyond VEGF/VEGFR2 signaling[J].J Vas Res,2022,59(2):78-89.
[14] MABETA P,STEENKAMP V.The VEGF/VEGFR axis revisited:implications for cancer therapy[J].Int J Mol Sci,2022,23(24):15585.
[15] SAEED A,PARK R,SUN W.The integration of immune checkpoint inhibitors with VEGF targeted agents in advanced gastric and gastroesophageal adenocarcinoma:a review on the rationale and results of early phase trials[J].J Hematol Oncol 2021,14(1):13.
[16] FUKUOKA S,HARA H,TAKAHASHI N,et al.Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer:an open-label,dose-escalation,and dose-expansion phase Ib trial(REGONIVO,EPOC1603)[J].J Clin Oncol,2020,38(18):2053-2061.
[17] YANG X,LIAO H Y,ZHANG H H.Roles of MET in human cancer[J].Clin Chim Acta,2022,525:69-83.
[18] TO K K W,CHO W C S.Mesenchymal epithelial transition(MET):a key player in chemotherapy resistance and an emerging target for potentiating cancer immunotherapy[J].Current Cancer Drug Targets,2022,22(4):269-285.
[19] AYOUB N M,IBRAHIM D R,ALKHALIFA A E.Overcoming resistance to targeted therapy using MET inhibitors in solid cancers:evidence from preclinical and clinical studies[J].Med Oncol,2021,38(12):143.
[20] GARON E B,BRODRICK P.Targeted therapy approaches for MET abnormalities in non-small cell lung cancer[J].Drugs,2021,81(5):547-554.
[21] YAMASAKI A,MIYAKE R,HARA Y,et al.Dual-targeting therapy against HER3/MET in human colorectal cancers[J].Cancer Med,2023,12(8):9684-9696.
[22] THOMAS A,SLADE K S,BLAHETA R A,et al.Value of c-MET and associated signaling elements for predicting outcomes and targeted therapy in penile cancer[J].Cancers,2022,14(7):1683.
[23] ZHANG Z,LI D,YUN H,et al.Opportunities and challenges of targeting c-Met in the treatment of digestive tumors[J].Front Oncol,2022,12:923260.
[24] DONG Y,XU J,SUN B,et al.MET-targeted therapies and clinical outcomes:a systematic literature review[J].Mol Diagn Ther,2022,26(2):203-227.
[25] APARICIO T,COZIC N,FOUCHARDIERE C,et al.The activity of crizotinib in chemo-refractory MET-amplified esophageal and gastric adenocarcinomas:results from the AcSe-crizotinib program[J].Target Oncol,2021,16(3):381-388.
[26] BAGCHI S,YUAN R,ENGMELAN E G.Immune checkpoint inhibitors for the treatment of cancer:clinical impact and mechanisms of response and resistance[J].Annu Rev Pathol,2021,16:223-249.
[27] DUBOIS M,LISCIA N,BRUNETTI O,et al.The role of immune checkpoint inhibitors in the treatment sequence of advanced gastric or gastro-esophageal junction cancer:a systematic review and meta-analysis of randomized trials[J].Crit Rev Oncol Hematol,2022,173:103674.
[28] YUKAMI H,KAWAZOE A,LIN Y T,et al.Updated efficacy outcomes of anti-PD-1 antibodies plus multikinase inhibitors for patients with advanced gastric cancer with or without liver metastases in clinical trials[J].Clin Cancer Res,2022,28(16):3480-3488.
[29] LIU S Y,LI Z H,LI H H,et al.TGF beta-associated signature predicts prognosis and tumor microenvironment infiltration characterization in gastric carcinoma[J].Front Immunol,2022,13:968165.
[30] JANJIGIAN Y Y,KAWAZOE A,YANEZ P E,et al.Pembrolizumab plus trastuzumab and chemotherapy for HER2+metastatic gastric or gastroesophageal junction(G/GEJ) cancer:initial findings of the global phase 3 KEYNOTE-811 study[J].J Clin Oncol,2021,39(15):4013.
[31] LIN G T,LIU Z Y,SHANG-GUAN Z X,et al.Comparison of the efficacy between immunochemotherapy and chemotherapy in gastric cancer accompanied with synchronous liver metastases:a real-world retrospective study[J].Cancer Med,2023,12(11):12221-12233.
[32] CATENACCI D V,ROSALES M,CHUNG H C,et al.MAHOGANY:margetuximab combination in HER2(+) unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma[J].Future Oncol,2021,17(10):1155-1164.
[33] MCLAUGHLIN M,PATIN E C,PEDERSEN M,et al.Inflammatory microenvironment remodelling by tumour cells after radiotherapy[J].Nat Rev Cancer,2020,20(4):203-217.
[34] TAKEDA K,SAKAYAUCHI T,KUBOZONO M,et al.Palliative radiotherapy for gastric cancer bleeding:a multi-institutional retrospective study[J].Bmc Palliative Care,2022,21(1):52.
[35] NG S P,LEONG T.Role of radiation therapy in gastric cancer[J].Ann Surg Oncol,2021,28(8):4151-4157.
[36] MAYINGER M,LUDWIG R,CHRIST S M,et al.Benefit of replanning in MR-guided online adaptive radiation therapy in the treatment of liver metastasis[J].Radiat Oncol,2021,16(1):84.
[37] YAMAGUCHI H,HONDA M,HAMADA K,et al.The effectiveness of proton beam therapy for liver metastatic recurrence in gastric cancer patients[J].Jpn J Clin Oncol,2020,50(8):903-908.
[38] LI N,WANG G,DUAN G,et al.Clinical observation of transcatheter arterial chemoembolization in super-aged patients with advanced gastric cancer[J].Support Care Cancer,2022,30(2):1441-1450.
[39] XU H,MIN X,REN Y,et al.Comparative study of drug-eluting beads versus conventional transarterial chemoembolization for treating peculiar anatomical sites of gastric cancer liver metastasis[J].Med Sci Monit,2020,26:e922988.
[40] WANG K,WANG H Y,LV Y,et al.Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis:a case report[J].Ann Palliat Med,2021,10(1):803-809.
[41] JOSHI S S,BADGWELL B D.Current treatment and recent progress in gastric cancer[J].CA Cancer J Clin,2021,71(3):264-279.
[42] ZhANG Y Q,XU X Q,HU C,et al.Trastuzumab in combination with chemotherapy for HER2-positive metastatic gastric cancer patients underwent conversion therapy[J].Transl Cancer Res,2022,11(7):2145-2156.
[43] YOSHIDA K,YASUFUKU I,TERASHIMA M,et al.International retrospective cohort study of conversion therapy for stage IV gastric cancer 1(CONVO-GC-1)[J].Ann Gastroenterol Surg,2022,6(2):227-240.
[44] ZHAORAN S,MIN K,KUANSHAN S,et al.S-1 Combined with apatinib and trans-arterial chemotherapy and embolization for conversion therapy of unresectable locally advanced gastric cancer[J].J Surg Res,2022,270:162-168.
[45] CHENG Y X,PENG D,QIAN K,et al,Successful conversion therapy through gastric transcatheter chemoembolization in advanced gastric cancer:a case report[J].Asian J Surg,2021,44(6):867-868.
[46] DENG Y Y,JIANG D Y,ZHU P F,et al.Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients:a retrospective cohort study[J].World J Surg Oncol,2023,21(1):129.
[47] LIANG H.PD-1 inhibitors provide new opportunities in conversion therapy for stage IV gastric cancer[J].Cancer Biol Med,2022,19(5):565-568.
[48] NAMIKAWA T,MARUI A Y K,YOKOTA K,et al.Successful conversion surgery for advanced gastric cancer with multiple liver metastases following ramucirumab plus paclitaxel combination treatment[J].In Vivo,2021,35(7):2929-2935.
[49] MIENO H,YAMASHITA K,HOSODA K,et al.Conversion surgery after combination chemotherapy of docetaxel,cisplatin and S-1(DCS) for far-advanced gastric cancer[J].Surgery Today,2017,47(10):1249-1258.
[50] SATO Y,OHNUMA H,NOBUOKA T,et al.Conversion therapy for inoperable advanced gastric cancer patients by docetaxel,cisplatin,and S-1(DCS) chemotherapy:a multi-institutional retrospective study[J].Gastric Cancer,2017,20(3):517-526. |
